Viatris以16.5亿美元现金收购Pacira BioSciences，每股36.50美元、溢价45%，补强非阿片类止痛药组合

Viatris boosts pain drug portfolio with $1.7B buyout of Pacira | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Dive Brief
Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection.
Published Oct. 8, 2026
Jonathan Gardner
Senior Reporter
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
Viatris headquarters in Pittsburgh, PA.
Courtesy of Viatris
Dive Brief:
Viatris is expanding its pain-drug portfolio, announcing Thursday it is
buying Pacira BioSciences for $1.65 billion
to acquire medicines that treat post-surgical and arthritis pain.
Per deal terms, Viatris will pay Pacira investors $36.50 per share in cash, a 45% premium over Wednesday’s closing price. The deal is expected to close by the end of 2026, Viatris said.
Pacira’s two biggest drugs booked $692 million in sales in 2025, growing about 4% over 2024. Viatris said it “expects to expand the products' reach across select markets within its global infrastructure.”
Dive Insight:
Pacira’s main products are the post-surgical pain drug Exparel and a therapy called Zilretta that treats knee pain associated with osteoarthritis. Both are novel formulations of the old and now-generic non-opioid pain relievers bupivacaine and triamcinolone.
Viatris has its own pain medications in Celebrex and Relpax, and could soon launch a fast-acting
version of the drug meloxicam
if the Food and Drug Administration
clears it by a Dec. 27
decision deadline. Adding Pacira’s portfolio to the mix further fits with its strategy of “purchasing on-market, commercial assets,” Leerink analyst Daniel Clark wrote in a client note.
Clark added that the transaction should be “immediately accretive” to revenue and help grow earnings into the 2030s.
Still, generic erosion of Exparel is likely to begin in early 2030 because of patent settlements Pacira made last year with Fresenius Kabi and a Hengrui Pharma subsidiary. Those deals allow the two companies to begin marketing “high single digit” percentages of total U.S. volume and escalate to the 30% range within three years.
That settlement was helped along by manufacturing patents won in 2024 that now have pushed Exparel
intellectual property protections
out to 2044, according to the FDA’s Orange Book. Two other manufacturers are challenging those patents, however.
Patents covering Zilretta, meanwhile, are
set to expire in 2031
.
Viatris said Thursday that it “plans to leverage its intellectual property expertise and proven ability to extend product lifecycles and sustain meaningful sales” after generics arrive.
In initiating coverage on Pacira in September, Clark noted that Exparel’s growth has been constrained by hospital formularies that have been reluctant to add it to their usual post-surgical protocols. The drug recently won coverage from large insurer United Healthcare, leading Clark to believe there weren’t any other growth opportunities that could exceed current Wall Street targets.
With this transaction, “we do not anticipate a meaningfully different near-term trajectory, but do like that [Viatris] is executing against its capital deployment strategy and adding what should be steady sources of growth and margin expansion into the 2030s,” wrote Clark, who also covers Viatris.
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Pharma
,
Deals
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive
//
Emerging biotech
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
By Gwendolyn Wu •
April 28, 2026
Getty Images
Deep Dive
//
State of Play
Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of research practically overnight.
By Ben Fidler •
March 4, 2025
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Tria…
From IQVIA
October 07, 2026
Archō’s ELAVAY Cardiometabolic Report Names Eli Lilly the Company Diabetes Advocates Trust Most
From Archō Advocacy, LLC
October 07, 2026
ACTO Named a Luminary in Everest Group’s “Innovation Watch: Agentic AI in Life Sciences Commer…
From ACTO
October 05, 2026
New Science Paper Identifies a Shared Adenosine Signaling Pathway That Causes Cardiac Fibrosis
From Greenstone Biosciences
September 24, 2026
Editors' picks
Permission granted by Daiichi Sankyo
ASCO25
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.
By Ned Pagliarulo •
June 4, 2025
Adeline Kon / BioPharma Dive/BioPharma Dive
Deep Dive
//
Patent thickets
Drug patents protect pharma profits. Track when they’ll expire.
BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.
By Jonathan Gardner •
Updated Aug. 4, 2026
Latest in Deals
In the hunt for reverse merger targets, Caribou could be prized game
By Jacob Bell
GE HealthCare to acquire Sofie Biosciences for $945M
By Susan Kelly
Shionogi pays $2B to acquire a rare disease startup
By Jonathan Gardner
Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug
By Ben Fidler
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell